TLDR:
- Sava, a London-based health monitoring company, raised $8M in Seed funding led by Balderton Capital and Exor Ventures
- The company plans to expand its team, design its product line with manufacturing capability, and demonstrate the platform’s clinical performance
In a recent development, Sava, a London-based health monitoring company, has successfully raised $8M in Seed funding. The round was led by Balderton Capital and Exor Ventures, showcasing strong investor interest in the company’s wearable biosensor platform. Founded by Renato Circi and Rafael Michali, Sava is focused on developing a novel microsensor technology that can monitor biomarkers in the body in real-time, with a special emphasis on glucose monitoring.
One of the key milestones for Sava was gaining approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with clinical trials on patients with diabetes. This approval will help Sava validate its breakthrough technology on a larger scale and demonstrate the platform’s clinical performance. The company plans to use the funds from the Seed round to expand its team, design its product line with manufacturing capability, and conduct further research and development to enhance its offerings.
With an upcoming clinical study scheduled to start with investigators from the Universities of Oxford and Cambridge, Sava’s microsensor technology is poised to offer pain-free, real-time insights for users. This innovative approach to health monitoring has the potential to revolutionize how individuals manage their health conditions and stay informed about their well-being.
